Genomma Lab Internacional Sab De Cv Class B · BMV:LAB/B
Genomma Lab Internacional Sab De Cv Class B — Investor Presentation (December 2025)
32 slides from Genomma Lab Internacional Sab De Cv Class B's investor presentation, December 2025
Slide 1: Genomma Lab Internacional Investor Relations
Genomma Lab.°® Internacional Genomma Lab Investor Relations
Slide 2: Forward-looking statements disclaimer
This presentation may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limit
Slide 3: About Genomma Lab
About Genomma Lab GENOMMA LAB pevetops, MANUFACTURES AND MARKETS 4 PORTFOLIO OF 60 PREMIUM BRANDED PRODUCTS FOR MASS CONSUMPTION, MANY OF WHICH ARE LEADERS IN THEIR CATEGORIES BUSINESS UNITS REGIONS 44% 51% 34% 47% Led oe Ss MEXICO », 5% a BEVERAGES
Slide 4: Strong brand heritage: OTC portfolio
Strong brand heritage OTC portfolio Cough & Cold Analgesics Derma OTC
Slide 5: Strong brand heritage: Personal care portfolio
Strong brand heritage Personal care portfolio Haircare Skincare
Slide 6: Strong brand heritage: Beverage portfolio
Strong brand heritage Beverage portfolio SUEROX; SUERO SUER(. SUEROX sUEROX SUERO FORMULAHIDRATANTE — [ORMULAWIORATANTED, FORHULAHIDRATARTE
Slide 7: Strong geographical footprint
Strong geographical footprint >» UNITED STATES } CARICAM Guatemala . MEXICO — Honduras ANDEAN CLUSTER El Salvador Belice Costa Rica Panama Colombia Peru Ecuador Bolivia Nicaragua SOUTHERN REGION Argentina Chile Paraguay Uruguay BRAZIL
Slide 8: State-of-the-art manufacturing facility
State-of-the-art manufacturing facility International Finance Corporation WORLD BANK GROUP ENHANCED VALUE EQUATION SUPERIOR PRODUCT QUALITY 4 @IFC “! IDB us$ 100 mm 8-YEAR LOAN HIGHER GROSS MARGIN RELIABLE PRODUCT SUPPLY
Slide 9: Traditional channel
Traditional channel Robust distribution network Pharmacies Supermarkets Discounters & Convenience
Slide 10: Superior retail execution and in-store media
Su pe rior Competitive edge: in-store media retail execution Gen expertos program +945 field merchandisers CIATICA, LUMBAR AlliviaDOLor INTENSO —Alllivia C/471C2, CM.
Slide 11: FT1 TV own production studio
FT1 TV Own production studio advertisers Multimedia capabilities in Latam 1,700 new spots per year
Slide 12: 2022 results: gross margin, EBITDA margin, EPS, ROIC
2022 Gross margin 60.4% EBITDA margin 20.5% EPS MXN $1.33 ROIC 13.5% MXN $1.61 Genomma Lab* INVESTOR RELATIONS, 10
Slide 13: Strong growth track-record
Strong growth track-record Consolidated net sales 5.5% CAGR $18,607 $17,541 $16,820 $16,467 $15,460 $13,870 $12,713 % growth 2019 2020 2021 2022 2023 2024 2025 Data in MXN millions 2019 Consolidated EBITDA 2020 8.8% CAGR 2021 2022 2023 $4,270 $4,101 2024 2025 % margin
Slide 14: Slide 14
Slide 15: 1.1B MXN productivity to self-fund growth and 2026 recovery plan
We delivered 1.1B MXN in productivity to self-fund growth investments and support our 2026 recovery plan Data in MXN millions Source: Genomma Lab Internacional
Slide 16: Delivering +$1.4B MXN incremental sales (risk-adjusted)
Delivering +$1.4B MXN incremental sales (risk-adjusted) Data in MXN millions Source: Genomma Lab Internacional
Slide 17: Incremental sales: +$550 million MXN
Incremental sales: +$550 million MXN Data in MXN millions Source: Genomma Lab Internacional
Slide 18: Expanding Mexico distribution network
Expanding Mexico distribution network Direct distribution in the Mexican traditional channel 504 Operating routes in Mexico 2 Targeted new Mexico +270K POS covered After expansion ORTH EAST @ Operating routes @ Expanding routes
Slide 19: Incremental sales: +$680 million MXN
Incremental sales: +$680 million MXN Perfect Store Recommendations, Ramp Up Independent Pharmacies & Improved Visibility Summer & Winter Analgesics Season Top Notch InStore Plan Execution
Slide 20: +$570 million MXN
+$570 million MXN OTC Haircare Beverages Skincare • 25 pharma registrations • Improved clean • New forms • Democratizing to be approved by performance high-end skin 2026 • Expanded routine • Renewed image • Clean formulas & • Conquering new fresh design segments across • Increasing categories consum
Slide 21: Multimedia reach and social commerce / influencers
Multumedia Reach Social Commerce / Optimized Influencers Production • +28% increased • Mass micro influencers & • Digital native assets & user investment brand embassadors generated content • Improved media • Driving traffic to e-commerce • AI generated content & direct conversion • Increasing digit
Slide 22: Incremental sales: +$230 million MXN
Incremental sales: +$230 million MXN 900 800 $680 700 600 500 $450 400 300 200 100 - 2025E 2026E Data in MXN millions Source: Genomma Lab Internacional
Slide 23: Improving OTC visibility in discounters channel
Improving OTC visibility in discounters channel $230 M Incremental sales 2026 +1.2k OTC Endcaps
Slide 24: Incremental sales: +$310 million MXN
Incremental sales: +$310 million MXN $1,365 $1,055 $829 $715 $572 2022 2023 2024 2025E 2026E Data in MXN millions Source: Genomma Lab Internacional
Slide 25: +$180 million MXN
+$180 million MXN Source: Genomma Lab Internacional
Slide 26: Momentum rebuilding and 2026 EBITDA outlook
1 Momentum rebuilding Progressive return to our historical growth rates, as Mexico normalizes and execution ramps up 2 Q1 2026 picking up Sell-in growth between low-single digits and flat, as we complete trade inventory normalization in Mexico 3 Healthy EBITDA at ~23.0%–23.5% in FY 2026 While we ste
Slide 27: 25,0 20,0 15,0 10,0 5,00 -
25,0 00 20,0 00 15,0 00 10,0 00 5,00 0 -
Slide 28: There is more to conquer
There is more to conquer Our growing market shares have a huge potential Beverages Personal Care oTCc Including Brazil Infant Nutrition SHARE OF MARKET Mexico + Latam 5.3% 2.8% 8.2% 5.3% 1.4% CATEGORY SIZE Mexico + Latam US$ 2.4 billion US$ 10.5 billion US$ 4.9 billion US$8.0 billion US$ 24 billion
Slide 29: Brand innovation levers by business unit
BU Brand Better Fresh Increased Expanded New New New New Int. Formula design routine use / dem forms functions sizes category Roll-out Skincare CICATRICURE ✓ ✓ ✓ ✓ ✓ ✓ ✓ TEATRICAL ✓ ✓ ✓ ✓ ✓ ✓ ✓ ASEPXIA ✓ ✓ ✓ ✓ ✓ ✓ ✓ Haircare TIO NACHO ✓ ✓ ✓ ✓ ✓ ✓ ✓ VANART ✓ ✓ ✓ ✓ OTC COUGH & COLD ✓ ✓ ✓ ✓ ✓ ANALGESIC
Slide 30: Strong OTC registry pipeline
Strong OTC registry pipeline Improved momentum in OTC registry submission & approvals Submitted OTC registries 98 ' 2022 2023 2024 126
Slide 31: Capital allocation priorities
Capital allocation priorities 1. Invest in the core business Product innovation Distribution expansion In-store execution Brand communication 2. Total shareholder return ¢ $800 million annual dividend priority * Strategic buybacks
Slide 32: Genomma Lab
Genomma Lab.°® GENOMMA LAB
Genomma Lab Internacional — Investor Presentation (December 2025) on 6ix